EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Raman imaging uncovers Ebracteolatain A's subtype-selective metabolic reprogramming in luminal versus triple-negative breast cancer cells

Chengjian Li, Wentao Zhang, Haoyu Feng, YanJun Luo, Cheng Chen, Xia Huang, Liang Zhao

Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy · 2026

DOI: 10.1016/j.saa.2025.127294 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy, 2026. Verfasst von Chengjian Li und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Shanghai, Baoshan Luodian Hospital, Baoshan District, Shanghai 201908, China; Luodian Clinical Drug Research Center, Institut…. Hauptthemen laut MEDLINE: Spectrum Analysis, Raman, Triple Negative Breast Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 68 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Xi’an Jiaotong-Liverpool University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Ebracteolatain A (EA), a potential anti-cancer agent, has demonstrated efficacy against breast cancer through protein kinase D1 inhibition. However, its effects on cellular metabolic reprogramming and activity against aggressive cancer subtypes remain poorly understood. Using confocal Raman spectroscopy coupled with machine learning, we investigated spatial and quantitative metabolic alterations induced by EA (0, 5, 10 μM) in luminal (MCF-7) and triple-negative (SUM149) breast cancer cells at single-cell resolution. Our integrated analysis revealed distinct, concentration-dependent metabolic responses between subtypes. While both cell lines exhibited conserved EA-induced increases in glucose (1123 cm-1) and lipid (1440 cm-1) levels with protein depletion (2928 cm-1), MCF-7 cells displayed significantly greater metabolic vulnerability. These proliferative cells showed progressive phenylalanine reduction (1003/1171 cm-1) and developed characteristic perinuclear lipid-protein droplets at 5 μM EA, progressing to complete biomolecular disorganization at cytotoxic concentrations (10 μM). In contrast, SUM149 cells maintained metabolic stability, demonstrating sustained nucleic acid production (1223 cm-1) and preserved subcellular integrity throughout treatment. Multivariate analysis confirmed this differential metabolic remodeling sensitivity, with linear discriminant analysis showing pronounced dose-dependent clustering in MCF-7 cells (Mahalanobis distance = 5.90) compared to SUM149 populations (distance = 3.72). These findings not only elucidate EA's subtype-specific mechanisms of action but also validate the combined Raman spectroscopy-machine learning platform as a powerful tool for pharmacometabolomic assessment. This approach provides spatial and quantitative insights into cancer cell metabolic adaptation, offering new opportunities for targeted therapeutic development.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Spectrum Analysis, RamanTriple Negative Breast NeoplasmsHumansFemaleCell Line, TumorMCF-7 CellsMetabolic Reprogramming

Stichwörter der Autor:innen

Breast cancer heterogeneityEbracteolatain AMachine learningMetabolic reprogrammingRaman imagingTherapeutic resistance

Autor:innen und Institutionen

  • Department of Pharmacy, Shanghai, Baoshan Luodian Hospital, Baoshan District, Shanghai 201908, China; Luodian Clinical Drug Research Center, Institute for Translational Medicine Research, Shanghai University, Shanghai 2…
  • Department of Biosciences and Bioinformatics, Xi'an Jiaotong-Liverpool University, Suzhou, Jiangsu 215123, China.
  • Shanghai Dband Medical Biotech Co.,Ltd, Shanghai 201800, China.
  • Emei Rehabilitation and Recovery Center, Leshan, Sichuan 614200, China.
  • Department of Biosciences and Bioinformatics, Xi'an Jiaotong-Liverpool University, Suzhou, Jiangsu 215123, China; Department of Biosciences and bioinformatics, Suzhou Municipal key Lab AI4Health, School of Science, Xi'a…

Förderung

  • Xi’an Jiaotong-Liverpool University

Zitieren

APA

Li, C., Zhang, W., Feng, H., Luo, Y., Chen, C., Huang, X., & Zhao, L. (2026). Raman imaging uncovers Ebracteolatain A's subtype-selective metabolic reprogramming in luminal versus triple-negative breast cancer cells. Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy. https://doi.org/10.1016/j.saa.2025.127294

Vancouver

Li C, Zhang W, Feng H, Luo Y, Chen C, Huang X, et al. Raman imaging uncovers Ebracteolatain A's subtype-selective metabolic reprogramming in luminal versus triple-negative breast cancer cells. Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy. 2026. doi:10.1016/j.saa.2025.127294

BibTeX
@article{Li2026,
  author = {Li, Chengjian and Zhang, Wentao and Feng, Haoyu and Luo, YanJun and Chen, Cheng and Huang, Xia and Zhao, Liang},
  title = {Raman imaging uncovers Ebracteolatain A's subtype-selective metabolic reprogramming in luminal versus triple-negative breast cancer cells},
  journal = {Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy},
  year = {2026},
  doi = {10.1016/j.saa.2025.127294}
}
Kostenlos starten →